ADXN - רווח לפני ריבית, מסים ופחת Addex Therapeutics Ltd.

Addex Therapeutics (ADXN) combines the fine-tuning of brain receptors to combat dyskinesia with the development of advanced treatments for dystonia. Monitoring EBITDA_Co allows these scientific achievements to be weighed against financial stability, where the current mark stands at 0.00. High confidence from the global neurobiology community and partnerships with pharma behemoths confirm the company's status as a reliable innovator in Parkinson's disease therapy.
Addex Therapeutics Ltd (ADXN) - פילוחי מדדים ודוחות פיננסיים

Cash flow analysis minimizes risks, confirming the ability of Addex Therapeutics (ADXN) to monetize CNS modulator patents through stable demand for chronic diseases. The current value of 0.00 reflects daily operating profit before taxes and interest, while EBITDA dynamics allow for an assessment of capital stability and the business's real liquidity during periods of market volatility.